



Monoclonal Antibodies

4th
Annual

Achieving faster development, production and modification of antibody-based therapeutics

27th - 28th March 2008, etc.venues Bonhill House, London, UK

Key Speakers

Dr Valerie E. Quarmby Associate Director, Bioanalytical Research and Development, **Genentech**

Dr David Lowe, Head of Display Technology, **MedImmune**

Dr Robert J. Lutz, Executive Director, Preclinical Development, **ImmunoGen**

Dr Henning Dierks, Strategic Marketing Manager, BioProcess, **GE Healthcare**

Philippe Stas, Chief Operating Officer, **AlgoNomics**

Tobias Raum Director, Human Antibody Technology, **Micromet**

Professor Andrew J. R. Porter, Chair in Molecular & Cell Biology, **University of Aberdeen**

Dr Uwe Gottschalk, Group Vice President of Purification Technologies, **Sartorius Stedim**

Dr Matthew Baker, Chief Scientific Officer, **Antitope**

Dr Martyn Robinson, VP - Antibody Project Biology, **UCB Celltech**

Professor Herta Steinkellner, Institute of Applied Genetics and Cell biology, **BOKU-Wien**

Rebecca Lawrence, Senior Associate, **Powell Gilbert**



Media Partners



Organised By



For any enquiries please call +44 (0) 158083 1877

At an estimated worldwide market value of \$24 billion in 2007, monoclonal antibodies (mAbs) for therapeutic use are poised to reach an estimated value of \$47 billion by 2012 for a CAGR of 14%. (BCC Research, 2007)

Dear Colleague,

Monoclonal antibody therapies have been posting the fastest growth within the protein therapeutics market easily outstripping the growth rate of 0.6% in the more traditional, small molecules market. With key products forecast to record peak sales growth and the launch of new products, this rapid expansion is set to continue. In addition to occupying a sector of the market that is insulated from generic competition, mAbs have the advantage of primarily addressing high unmet need therapy areas such as oncology and AID.

Hundreds of monoclonal antibodies are presently undergoing various stages of clinical development. Many in the industry are utilizing ex vivo libraries and development of transgenic mice which generate antibodies with a human protein sequence instead of a mouse protein sequence, thus allowing for the development of mAbs with higher human composition. Alliances between pharmaceutical and biotech companies are a key driver of the current mAb market. With big pharma backing smaller biotech companies in their research and clinical programs, and thus funding vital manufacturing facilities, there is little reason why the mAb market will not continue to flourish.

Delivered by a panel of expert speakers Visiongain's 4th Annual Monoclonal Antibodies in Therapeutics, will provide the ideal forum for leading companies, and those with emerging products or technologies to collaborate and exchange ideas. This two-day programme will examine strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this highly exciting market sector, and discuss the advantages and limitations of antibody-based products, patent issues and applicability.

Why you should attend?

- ✓ Assess the strategic decisions which have been implemented by key mAb market players
- ✓ Examine the current technologies underlying the mAb market and discuss the effects of new technologies on this market
- ✓ Learn about recent advances in therapeutic applications
- ✓ Examine the market potential of promising drugs under development
- ✓ Address challenges to the research, production modification of mAbs
- ✓ Develop new antibody therapies with strong efficacy and good side effect profiles
- ✓ Form strategic alliances and improve on existing partnerships
- ✓ Analyse the current patent landscape and discuss future IP issues
- ✓ Discover new directions in antibody research

I look forward to seeing you there

Yours sincerely,



Andrea Charles
Senior Conference Producer
Pharmaceutical Division

Who Will Attend:

VPs, Directors, Heads and Managers of:

- Research & Development
- Preclinical Development
- Clinical Development
- Antibody Development
- (Clinical) Oncology
- Oncology Research
- Oncology Discovery
- New Product Development
- Business Development
- Protein Engineering
- Antibody Engineering
- Immunology (Research)
- Clinical Diagnostics
- Oncology Research
- Marketing
- Licensing

Media Partners:



PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US.

For further information please email: corporate@pharmiweb.com



BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world's biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities.

For further information please visit www.biotechnology-europe.com

About visiongain:

Visiongain is a specialist business information company focused on providing cutting edge products and services across the Pharmaceutical/Biotech, Telecommunications, Defence and Finance sectors, which include reports, conferences, online daily news and offline news analysis and bespoke consultancy. With a commitment to innovation and excellence, visiongain offers flexible solutions to meet our clients' business intelligence needs, providing the right information at the right time to facilitate the commercial decision-making process. Our pharmaceutical products include Pharma Business Daily, the leading daily email newsletter for the pharmaceutical, biotech and healthcare industries, and a range of independent, high-quality, in-depth reports covering focused and topical areas of concern. Our pharmaceutical conferences address the hottest commercial, regulatory and technical topics and provide an ideal forum for debate and networking for pharmaceutical professionals from around the world.

For further information, please visit: www.visiongain.com

Pharma Business Daily

Bringing you up to the minute
breaking news for the
Pharmaceutical industry.

One e-mail, all the critical
news - for a free trial
Call: +44 (0) 158083 1877

Sponsorship and exhibition opportunities:

This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:

- Hosting a networking drinks reception
- Taking an exhibition space at the conference
- Advertising in the delegate documentation pack
- Providing branded bags, pens, gifts, etc.

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's Monoclonal Antibodies event, please contact:



Jon Goldhill

Tel: +44 (0)158083 1877

Email: conferences@leaddiscovery.co.uk

09:30 Registration and refreshments

Dr Valerie Quarmby
Associate Director, Bioanalytical Research & Development
Genentech

10:00 Opening address from the chair

10:10 Isolation and optimisation of therapeutic antibodies using display technologies

- Use of phage and ribosome display to isolate antibodies of interest
- Affinity optimisation of antibody therapeutics
- Case Studies

David Lowe
Head of Display Technology
MedImmune
(formerly Cambridge Antibody Technology)

10:50 Examining a rapid method for producing optimised therapeutic antibodies

- Assessing current antibody engineering platforms
- Examining the how a 'reference antibody' is converted into a high-affinity human antibody with conserved epitope binding
- Describing the benefits of humanising antibodies
- Investigating future therapeutic applications

11:30 Morning refreshments

11:50 Downstream processing 2008: More challenges ahead

- Upstream makes the pace: Benchmarks in biomanufacturing
- Chromatography: The Good, The Bad and The Ugly
- Virus and contaminant safety: GMP is a moving target
- Emerging Technologies: Boring but reliable
- Process Economy: Ways out of the fixed-cost trap

Dr Uwe Gottschalk
Group Vice President of Purification Technologies
Sartorius Stedim

12:30 Approaches to antibody purification - seamless transition from screening to commercial scale production

- High Throughput Process Development - PreDicator™
- Expendable column concept - Ready to Process™
- Commercial Scale production - AxiChrom™

Dr. Henning Dierks
Strategic Marketing Manager, BioProcess
GE Healthcare

13:10 Networking lunch

14:30 Antibody coated microcrystals for alternate delivery applications

Dr Barry D Moore
Chief Scientist
XstalBio

15:10 Immunogenicity screening of antibody therapeutics

- As the number of therapeutic antibodies on the market is steadily increasing, strategies are being defined to assess and address immunogenicity.
- A risk-assessment framework will be presented to assess both the likelihood and the severity of the immune responses induced.
- Pre-clinical strategies to optimally assess immunogenicity are formulated, looking at methods and tools to control or minimise antibody immunogenicity

Philippe Stas
CEO
AlgoNomics

15:50 Afternoon refreshments

16:10 Impact of immunogenicity on PK, PD, safety & efficacy of monoclonal antibody therapeutics in the clinic

- The importance of evaluating immunogenicity data in context
- Assessing clinical safety and efficacy data after an immune response occurs
- Discuss immunogenicity in the context of information from clinical trials on safety efficacy, pharmacokinetic and pharmacodynamic aspects of monoclonal antibody therapeutics

Dr Valerie Quarmby
Associate Director, Bioanalytical Research & Development
Genentech

16:50 Predicting and reducing immunogenicity in antibody therapeutics

- Risk factors in the immunogenicity of therapeutic antibodies
- Accurate detection of T cell epitopes in therapeutic antibodies
- Case studies highlighting the link between clinical immunogenicity and T cell epitopes
- Re-engineering therapeutic antibodies to avoid/remove T cell epitopes

Dr Matthew Baker
Chief Scientific Officer
Antitope

17:40 Closing remarks from the chair

17:45 Networking Drinks Reception

Take your discussions further and build new relationships in a relaxed and informal setting.

09:30 Registration and refreshments

10:00 Opening address

10:10 **Antibody-Maytansinoid conjugates for the treatment of Cancer: From the bench to the clinic**

- Achieves potent anti-tumor activity through target cell activation
- Maximizes the therapeutic potential of anti-cancer antibodies
- Tailorable linker technology for optimal therapeutic window
- Product candidates with superior preclinical properties are now being evaluated in clinical trials

Dr Robert J. Lutz
Executive Director, Preclinical Development
ImmunoGen

10:50 **Adecatumumab: A human antibody for tumor therapy**

- Generation of the fully human anti-EpCAM antibody Adecatumumab
- Assessment of preclinical efficacy of Adecatumumab
- Examining the safety of Adecatumumab in a Phase I clinical trial in prostate cancer patients
- Presenting Phase II clinical trial data
- Discussing the potential of Adecatumumab in eradicating cancer stem cells

Dr Tobias Raum
Director, Human Antibody Technology
Micromet

11:30 Morning refreshments

11:50 **Human monoclonal antibodies as anti-infective drugs**

- Concept of antibodies in infectious diseases
- Anti-infective mAb products in clinical development
- Strategies for design of anti-infective mAb products

12:30 **Immuno-modulation of bacterial cell to cell signalling**

CASE STUDY

- Quorum sensing in Gram negative bacteria
- Isolating and characterising anti-hapten antibodies
- in vitro bioassays and proof of concept studies leading to candidate identification

Professor Andrew J. R. Porter
Chair in Molecular & Cell Biology
University of Aberdeen

13:10 Networking lunch

14:30 **Sclerostin – a potential new antibody target for treating low bone mass disorders**

- The phenotype of patients with the high bone mass disorder sclerosteosis
- The identification by positional cloning of the gene encoding sclerostin from patients with sclerosteosis
- The effect of anti-sclerostin antibodies in a range of preclinical models
- The results from the first human study with an anti-sclerostin antibody

Dr Martyn Robinson
VP - Antibody Project Biology
UCB Celltech

15:10 **Immunomodulatory monoclonal antibodies: development and use**

- Exploring some of the antibodies in development or approved for immunomodulatory therapy
- Addressing the challenges and issues surrounding preclinical testing
- Overcoming the problems in extrapolating preclinical data to clinical trials in man

15:50 Afternoon refreshments

16:10 Presentation to be announced

16:50 **Rapid and efficient generation of glycan optimized IgGs in glyco-engineered plants**

- Elimination of immunogeni/antigenic N-glycan residues
- RNAi for glycan engineering in plants
- Products with a homogeneous G0 N-glycosylation profile
- Excellent in vivo activities

Professor Herta Steinkellner
Insitute of Applied Genetics and Cell biology
BOKU-Wien

17:30 Chair's closing remarks

17:40 End of conference

